December 11, 2010 -- GlaxoSmithKline will pay $70 million for Nanjiing MeiRui Pharma to gain access to China’s urology sector; Sanofi-Aventis in-licensed a technology patent from SIBS with potential for a novel anti-angiogenesis cancer drug; an Astra-Zeneca survey shows people believe China will be the world’s leader in innovation by 2020; Qinghai Gelatin will sell its Hezheng Pharma subsidiary to Lummy Pharma for $13.5 million; BioTime signed up Shanghai Genext Medical Technology to market its progenitor cells in China; Beike Biotech ended its JV with SiriCell Technologies; and China Pharma Holdings completed clinical trials of a generic form of the cholesterol drug Crestor®. More details….
